Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Int J Mol Sci. 2022 Dec 12;23(24):15768. doi: 10.3390/ijms232415768.
A series of novel 1,3,4-oxadiazole-artemisinin hybrids have been designed and synthesized. An MTT assay revealed that most of tested hybrids showed more enhanced anti-proliferative activities than artemisinin, among which A8 had the superior potency with IC values ranging from 4.07 μM to 9.71 μM against five tested cancer cell lines. Cell colony formation assays showed that A8 could inhibit significantly more cell proliferation than artemisinin and 5-fluorouracil. Further mechanism studies reveal that A8 induces apoptosis and ferroptosis in MCF-7 cells in a dose-dependent manner, and CYPs inhibition assays reveal that A8 has a moderate inhibitory effect on CYP1A2 and CYP3A4 in the human body at 10 μM. The present work indicates that hybrid A8 may merit further investigation as a potential therapeutic agent.
一系列新型 1,3,4-噁二唑-青蒿素杂合分子被设计和合成。MTT 检测结果显示,大多数测试的杂合分子显示出比青蒿素更强的抗增殖活性,其中 A8 具有更优异的活性,对五种测试的癌细胞系的 IC50 值范围为 4.07 μM 至 9.71 μM。细胞集落形成实验表明,A8 能比青蒿素和 5-氟尿嘧啶更显著地抑制细胞增殖。进一步的机制研究表明,A8 以剂量依赖的方式诱导 MCF-7 细胞凋亡和铁死亡,CYP 抑制实验表明,A8 在 10 μM 时对人体中的 CYP1A2 和 CYP3A4 具有中等抑制作用。本工作表明,杂合分子 A8 可能值得进一步研究作为一种有潜力的治疗剂。